I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced its financial results for the 12 months ended December 31, 2022, and provided key business updates.
I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced its financial results for the 12 months ended December 31, 2022, and provided key business updates.